Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.59 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.56 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.56 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.53 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1456458 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL19557778 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL1456455 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL12377250 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL4023787 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL1456463 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL277126 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| Hexadecanoic Acid Isopropylamide SCHEMBL1457147 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL12459875 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL5005939 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10016510-B2 | Immunogenic composition in emulsion form | Commissariat à l'énergie atomique et aux énergies alternatives (FR) | 2018-07-10 | — | — | US | disclosed |
| US-9968673-B2 | Immunogenic composition in emulsion form comprising two dispersed phases, one comprising an antigen and the other comprising an immunostimulating agent | Commissariat á l'ènergie atomique et aux ènergies alternatives (FR) | 2018-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10016510-B2 | Immunogenic composition in emulsion form | DEGS1, FCGRT, ACOX1 | FAAH 115/4885MEN1 2164/4885KMT2A 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.